Citigroup
VKTX icon

Citigroup’s Viking Therapeutics VKTX Stock Holding History

Citigroup’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
+30,000
New +$969K ﹤0.01% 3327
2025
Q4 		– Sell
-80,300
Closed -$2.11M – 6505
2025
Q3 		$2.11M Buy
+80,300
New +$2.4M ﹤0.01% 2634
2024
Q3 		– Sell
-15,400
Closed -$816K – 5808
2024
Q2 		$816K Buy
+15,400
New +$1.01M ﹤0.01% 3056
2024
Q1 		– Sell
-90,000
Closed -$1.67M – 5869
2023
Q4 		$1.67M Buy
+90,000
New +$1.18M ﹤0.01% 2395
2023
Q3 		– Sell
-40,000
Closed -$648K – 5811
2023
Q2 		$648K Buy
40,000
+34,700
+655% +$727K ﹤0.01% 3180
2023
Q1 		$88.2K Buy
+5,300
New +$54.7K ﹤0.01% 4075
2021
Q1 		– Sell
-64,800
Closed -$365K – 7458
2020
Q4 		$365K Buy
64,800
+21,800
+51% +$132K ﹤0.01% 4489
2020
Q3 		$250K Sell
43,000
-18,300
-30% -$126K ﹤0.01% 4449
2020
Q2 		$442K Buy
61,300
+4,100
+7% +$27.2K ﹤0.01% 4372
2020
Q1 		$268K Buy
57,200
+700
+1% +$4.3K ﹤0.01% 4477
2019
Q4 		$453K Buy
56,500
+20,000
+55% +$146K ﹤0.01% 4501
2019
Q3 		$251K Sell
36,500
-12,600
-26% -$93.6K ﹤0.01% 4953
2019
Q2 		$408K Buy
49,100
+24,300
+98% +$208K ﹤0.01% 4619
2019
Q1 		$247K Buy
24,800
+13,200
+114% +$110K ﹤0.01% 4901
2018
Q4 		$89K Sell
11,600
-10,800
-48% -$129K ﹤0.01% 5749
2018
Q3 		$390K Buy
+22,400
New +$267K ﹤0.01% 4569

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Citigroup's VKTX Position: Q2 2026 in Review

Citigroup increased its Viking Therapeutics (VKTX) stake by 168% in Q2 2026, buying an estimated $5.94M and bringing the position to 293,126 shares worth $11.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1507.

Citigroup first reported a position in VKTX in Q1 2016 and has held it in 34 quarters since. The position peaked at $22.9M in Q2 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Citigroup held 293,126 shares of Viking Therapeutics worth $11.4M as of Q2 2026.
  • Citigroup bought 183,831 Viking Therapeutics shares in Q2 2026, an estimated $5.94M.
  • Viking Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1507 holding.
  • Citigroup first reported a position in Viking Therapeutics in Q1 2016 and has held it in 34 quarters since.
  • Citigroup's Viking Therapeutics position peaked at $22.9M in Q2 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.